In AML cells, SAMHD1 knockout (THP-1 KO), SAMHD1 knockdown (OCI-AML3), and SAMHD1 depletion by transduction with Vpx-VLPs (THP-1 and OCI-AML3) markedly increased the efficacy of DAC treatment (3.5–37-fold), but not of AZA treatment (1.2–1.6-fold) (Fig. 3a, b; Supplementary Fig. 11). This evidence concerns the gene SAMHD1 and acute myeloid leukemia.